Has Novo Nordisk Cut the Price of Wegovy in the UK?

Has Novo Nordisk actually reduced the Wegovy price in the UK?

Novo Nordisk has announced intentions to lower the price of semaglutide in certain markets, and those announcements have been widely covered. For context on what the company has said publicly about pricing for Wegovy and Ozempic, the details of Novo Nordisk's pricing announcements are worth reading through carefully before drawing conclusions about what you might pay.

The honest answer for UK patients is that the manufacturer's list price is only one input into what a private provider charges. Pharmacy operating costs, clinical staffing, dispensing, support infrastructure and delivery all feed into the final number. A reduction at the manufacturer level does not automatically flow through to a lower price on your receipt. Some providers may adjust; others may not; and the picture continues to change as supply agreements, market dynamics and NHS commissioning decisions shift around this medicine. The Wegovy price cut question deserves a nuanced answer rather than a simple yes or no.

What is fixed and clear is the legal framework: Wegovy is a Prescription-Only Medicine regulated by the MHRA, and the NHS's guidance on semaglutide sets out what that means for how it can be supplied. No legitimate route bypasses clinical assessment.

What do UK private Wegovy prices actually include, and what might they not?

When you see a monthly figure for Wegovy from a private provider, the most important question is what that number covers. Some prices are medicine-only: the consultation, the prescription and any follow-up support are billed separately or simply not offered. Others bundle everything together. Those two models produce very different real-world costs, even when the headline figures look similar.

The full breakdown of how Wegovy is priced in the UK private market covers the kinds of things that commonly sit outside a headline rate: initial eligibility assessments, dose-review consultations, delivery charges, and the ongoing clinical oversight that a prescription medicine genuinely requires. Delivery costs alone vary widely between providers.

According to widely reported figures from August 2025, Eli Lilly raised the list price of Mounjaro's highest dose from around £122 to around £330 per four-week pen, which gives a rough sense of the market context in which Wegovy also sits. Novo Nordisk's pricing moves in the opposite direction are therefore notable. But for a specific dose, the 1mg Wegovy price illustrates how costs shift at different points in the titration schedule, which is worth understanding before you start treatment.

Is searching for the cheapest Wegovy actually the right approach?

It is a natural instinct. But for a prescription medicine, the price comparison that matters most is not which number is lowest; it is whether the clinical process behind that number is complete. A provider quoting a very low price may be absorbing costs elsewhere, or they may simply not be providing what a responsible service requires: prescriber review, identity verification, genuine medicine sourced through the licensed UK supply chain, and reliable aftercare if something goes wrong.

The MHRA has documented seizures of counterfeit weight-loss pens sold online, and patients drawn to unusually low prices have sometimes received medicines that were fake or unsafe. Verifying any online pharmacy on the GPhC register is a straightforward step that takes about two minutes and tells you whether the service dispensing your treatment is actually registered and inspected.

At nume, we are not trying to win on price. A single transparent charge covers the consultation, the prescription, the medicine, and free next-working-day delivery, your pen arrives via DPD in plain, unbranded packaging, tracked to your door. No subscription. No renewal without a fresh clinical review. That structure costs more to run than a form-only, post-only service. We think the difference is worth it. You can read more about how we work on our about us page and see the full picture of what is included when you look at Wegovy's cost in context.

How does this fit with NHS access to Wegovy?

NHS access to Wegovy is governed by NICE technology appraisal TA875, which recommends semaglutide for weight management only within specialist multidisciplinary services, for a maximum of two years, and with BMI and comorbidity thresholds that currently exclude the majority of people who would benefit. Waiting lists at those services are long in most parts of the country.

Whether Novo Nordisk's pricing decisions accelerate NHS commissioning is a policy question being debated at a level above individual patients. For now, the practical reality is that most people accessing Wegovy in the UK do so privately. If you want to understand whether you might be eligible for the NHS route or a private one, the Wegovy treatment guide covers both honestly, and our weight-loss treatment overview sets out the options side by side.

Starting a free consultation at our treatment page is the straightforward way to find out where you stand. A prescriber reviews your details the same day, not software, not a delayed queue. That matters regardless of what any manufacturer does with its pricing.